Other Urinary | Urinary Bladder, Phase II
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Volunteers
Health Professionals
What is the purpose of this trial?
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.
Approximately 140 patients are anticipated to be enrolled across approximately 50 sites from North America and Europe.
- Trial withGilead Sciences
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- Brittany Bordonaro
- Brooke Chaves
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Hari Deshpande, MD
- Harold Tara Jr, MD
- Jane Kanowitz, MD
- Jaykumar Thumar, MBBS, MD
- Joseph Kim, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Kayla Martello
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Laura Sabourin
- Lynn Mastrianni
- M. Sung Lee, MD
- Michael Cohenuram, MD
- Michael Hurwitz, MD, PhD
- Neal Fischbach, MD
- Osarugue Otasowie
- Renee Moye
- Sarah Carlson
- Stacey LaRosa
- Su Hsien Lim, MD
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated03/14/2024
- Study HIC#2000023211